Valvular & structural heart disease
Seven-Year Valve Durability With Transcatheter or Surgical Aortic Valve Replacement: An Ad Hoc Analysis of the PARTNER 3 Randomized Clinical Trial
Authors' conclusion
In this ad hoc analysis of a randomized clinical trial among low-risk patients with symptomatic severe aortic stenosis randomized to TAVR or surgery, both TAVR and surgery demonstrated comparable and sustained valve durability, with low and similar rates of SVD, all-cause BVF, and reintervention through 7 years.
Study context
- Population
- Low-risk patients with symptomatic severe AS, 71 centres in the US and Canada, enrolled March 2016–October 2017randomised
- Participants
- 1,000 patients
- Comparison
- Transcatheter aortic valve replacement (TAVR) vs surgery
- TAVRn = 495
- Surgeryn = 453reference
- Primary endpoint
- Stage 2 or 3 BVD related to SVD, thrombosis or endocarditis; all-cause BVF; SVD-related BVF; aortic valve reintervention (cumulative incidence, death as competing risk)
- Follow-up
- 7 years
Methodological detailsad hoc analysis, multicentre, 537 of 671 alive patients (80.0%) had echocardiographic analysis at 7 years
- Ad hoc analysis
- Multicentre
- 537 of 671 alive patients (80.0%) had echocardiographic analysis at 7 years
Primary result
As reported in the abstract
TAVR
- Stage 2 or 3 structural valve deterioration (SVD)-related bioprosthetic valve dysfunction (BVD)
- 7.3%
- All-cause bioprosthetic valve failure (BVF)
- 6.9%
- SVD-related BVF
- 3.9%
- Valve reintervention
- 6.0%
- Stage 2 or 3 thrombosis-related BVD
- 5.2%
- Stage 2 or 3 endocarditis-related BVD
- 0.4%
Surgery
- Stage 2 or 3 SVD-related BVD
- 7.6%
- All-cause BVF
- 7.5%
- SVD-related BVF
- 5.3%
- Valve reintervention
- 5.5%
- Stage 2 or 3 thrombosis-related BVD
- 0.9%
- Stage 2 or 3 endocarditis-related BVD
- 0.5%
Stage 2 or 3 structural valve deterioration (SVD)-related bioprosthetic valve dysfunction (BVD)
TAVR7.3%
Surgery7.6%
All-cause bioprosthetic valve failure (BVF)
TAVR6.9%
Surgery7.5%
SVD-related BVF
TAVR3.9%
Surgery5.3%
Valve reintervention
TAVR6.0%
Surgery5.5%
Stage 2 or 3 thrombosis-related BVD
TAVR5.2%
Surgery0.9%
Stage 2 or 3 endocarditis-related BVD
TAVR0.4%
Surgery0.5%
TAVR vs SurgeryHazard ratio (95% CI)P value
Stage 2 or 3 SVD-related BVD
0.96(0.59–1.57)
P = 0.88All-cause BVF
0.91(0.55–1.49)
P = 0.69SVD-related BVF
0.72(0.39–1.36)
P = 0.31Valve reintervention
1.09(0.62–1.90)
P = 0.77Stage 2 or 3 thrombosis-related BVD; most events within 3 years, few progressed to BVF
5.52(1.92–15.85)
P < 0.001Stage 2 or 3 endocarditis-related BVD
0.85(0.12–6.07)
P = 0.87Further findings
Alive and free of all-cause BVF · 7 years
P = 0.69
Original publication
Seven-Year Valve Durability With Transcatheter or Surgical Aortic Valve Replacement: An Ad Hoc Analysis of the PARTNER 3 Randomized Clinical Trial. JAMA Cardiol. Published 1 August 2026. doi:10.
Summarised from the published abstract; every number is checked against it